Pfizer Inc. (PFE) Stock Analysis
Pfizer Inc. (NYSE: PFE) is one of the world's largest biopharmaceutical companies, discovering and manufacturing drugs across vaccines, oncology, primary care, and rare diseases. Investors research Pfizer for its diversified product portfolio, dividend yield, and exposure to both established franchises and emerging therapeutic areas.
Get a full AI research report on PFE
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Pfizer Inc. do?
Pfizer generates revenue by developing, manufacturing, and marketing pharmaceutical products across three main segments: Biopharma (primary care and specialty care), PC1 (primary care), and Pfizer Ignite (emerging businesses). The company's revenue streams include blockbuster drugs like Eliquis (cardiovascular), Prevnar vaccines, Xeljanz (immunology), Vyndaqel (rare disease), and Paxlovid (COVID-19 treatment), along with oncology and anti-infective medicines sold globally.
Bull case
- ✓Forward P/E of 8.84 suggests the stock is trading at a significant discount to historical pharma averages, potentially offering value for long-term investors.
- ✓Gross margin of 74.8% and operating margin of 31.6% demonstrate strong pricing power and operational efficiency in a capital-intensive industry.
- ✓Dividend yield of 6.87% provides current income, though the payout ratio of 131% indicates dividends are supported by cash flow rather than earnings alone.
- ✓Diversified product portfolio across vaccines, oncology, primary care, and rare diseases reduces dependence on any single drug or therapeutic area.
- ✓Strong balance sheet with a current ratio of 1.25 and quick ratio of 0.85 indicates adequate liquidity to fund R&D and shareholder returns.
Bear case
- ✗Debt-to-equity ratio of 71.6% is elevated, reflecting significant leverage that constrains financial flexibility and increases interest expense obligations.
- ✗Payout ratio of 131% exceeds net income, meaning the company is returning more cash to shareholders than it earns, raising sustainability concerns.
- ✗Return on equity of 8.3% and return on assets of 5.7% are modest, suggesting the company generates limited profit per dollar of shareholder capital deployed.
- ✗PEG ratio of 2.96 indicates the stock may be expensive relative to expected earnings growth, depending on forward guidance assumptions.
- ✗Patent expirations and generic competition pose ongoing revenue headwinds for mature drug franchises in the primary care segment.
PFE valuation & financial health
Pfizer trades at a trailing P/E of 19.1 and forward P/E of 8.84, with the forward multiple suggesting market expectations for earnings growth or a one-time benefit. The company's net margin of 11.8% is healthy for pharma, but ROE of 8.3% and ROA of 5.7% lag industry leaders, reflecting the capital intensity of drug development and manufacturing. The debt-to-equity ratio of 71.6% is a notable concern; combined with a payout ratio exceeding 130%, the company is prioritizing shareholder returns over debt reduction. Gross margins of 74.8% demonstrate strong pricing, though operating leverage is constrained by R&D and regulatory costs typical of the sector.
The bottom line
Pfizer presents a mixed profile for investors weighing value against financial risk. The forward P/E and dividend yield offer apparent value, but the elevated debt load, unsustainable payout ratio, and modest returns on capital warrant careful scrutiny of cash flow sustainability and dividend policy. Key factors to monitor include patent cliff impacts on revenue, success of pipeline candidates in oncology and rare disease, debt reduction progress, and whether earnings growth can justify the forward valuation. The company's scale and diversified portfolio provide stability, but investors should assess whether the current risk-reward aligns with their portfolio objectives.
Frequently asked questions
What does Pfizer Inc. do?
Pfizer discovers, develops, manufactures, and sells biopharmaceutical products globally across three segments: Biopharma (primary care and specialty care), PC1, and Pfizer Ignite. The company's portfolio includes vaccines (Prevnar, Abrysvo), cardiovascular drugs (Eliquis), immunology treatments (Xeljanz, Enbrel), rare disease therapies (Vyndaqel), oncology products, and COVID-19 treatments (Paxlovid).
Is Pfizer a dividend stock?
Yes, Pfizer pays a dividend with a current yield of 6.87%, making it attractive to income-focused investors. However, the payout ratio of 131% exceeds net income, meaning dividends are supported by cash flow rather than earnings alone, which raises questions about long-term sustainability.
What is Pfizer's valuation?
Pfizer trades at a trailing P/E of 19.1 and forward P/E of 8.84, suggesting the market expects significant earnings growth or a one-time benefit. The PEG ratio of 2.96 indicates the stock may be expensive relative to growth expectations, depending on analyst forecasts.
What are Pfizer's main risks?
Key risks include a debt-to-equity ratio of 71.6%, a payout ratio exceeding 130% (raising dividend sustainability concerns), modest returns on capital (ROE 8.3%, ROA 5.7%), and exposure to patent expirations and generic competition on mature drugs.
How profitable is Pfizer?
Pfizer's net margin of 11.8% is solid for pharma, and gross margins of 74.8% demonstrate strong pricing power. However, ROE of 8.3% and ROA of 5.7% are modest, reflecting the capital intensity of drug development and the company's leverage.
Is Pfizer overvalued or undervalued?
The forward P/E of 8.84 suggests a discount to historical pharma averages, but the PEG ratio of 2.96 and elevated debt load complicate the valuation picture. Whether the stock is attractive depends on your view of earnings growth, dividend sustainability, and acceptable risk levels.
Research PFE with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.